These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1231 related articles for article (PubMed ID: 26877618)

  • 1. Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation.
    Song JL; Gao W; Zhong Y; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Wu H; Xu MQ; Chen ZY; Wei YG; Jiang L; Yang J
    World J Gastroenterol; 2016 Feb; 22(6):2133-41. PubMed ID: 26877618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steroid-free immunosuppression with low-dose tacrolimus is safe and significantly reduces the incidence of new-onset diabetes mellitus following liver transplantation.
    Castedal M; Skoglund C; Axelson C; Bennet W
    Scand J Gastroenterol; 2018 Jun; 53(6):741-747. PubMed ID: 29688072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher tacrolimus blood concentration is related to increased risk of post-transplantation diabetes mellitus after living donor liver transplantation.
    Song JL; Li M; Yan LN; Yang JY; Yang J; Jiang L
    Int J Surg; 2018 Mar; 51():17-23. PubMed ID: 29360611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ''Minimizing tacrolimus'' strategy and long-term survival after liver transplantation.
    Jia JJ; Lin BY; He JJ; Geng L; Kadel D; Wang L; Yu DD; Shen T; Yang Z; Ye YF; Zhou L; Zheng SS
    World J Gastroenterol; 2014 Aug; 20(32):11363-9. PubMed ID: 25170223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New-Onset Diabetes Mellitus in Liver Transplant Recipients With Hepatitis C: Analysis of the National Database.
    Li Z; Sun F; Hu Z; Xiang J; Zhou J; Yan S; Wu J; Zhou L; Zheng S
    Transplant Proc; 2016; 48(1):138-44. PubMed ID: 26915859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for development of new-onset diabetes mellitus and progressive impairment of glucose metabolism after living-donor liver transplantation.
    Abe T; Onoe T; Tahara H; Tashiro H; Ishiyama K; Ide K; Ohira M; Ohdan H
    Transplant Proc; 2014 Apr; 46(3):865-9. PubMed ID: 24767367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus-related adverse effects in liver transplant recipients: its association with trough concentrations.
    Varghese J; Reddy MS; Venugopal K; Perumalla R; Narasimhan G; Arikichenin O; Shanmugam V; Shanmugam N; Srinivasan V; Jayanthi V; Rela M
    Indian J Gastroenterol; 2014 May; 33(3):219-25. PubMed ID: 24740447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower tacrolimus trough levels in the late period after living donor liver transplantation contribute to improvements in long-term clinical outcomes.
    Geng L; Wang LD; Huang JJ; Shen T; Wang ZY; Lin BY; Ye YF; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2018 Jun; 17(3):204-209. PubMed ID: 29807766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.
    Boillot O; Mayer DA; Boudjema K; Salizzoni M; Gridelli B; Filipponi F; Trunecka P; Krawczyk M; Clavien PA; Ducerf C; Margarit C; Margreiter R; Pallardo JM; Hoeckerstedt K; Pageaux GP
    Liver Transpl; 2005 Jan; 11(1):61-7. PubMed ID: 15690537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of four steroid-minimization protocols in liver transplant recipients: 3-year follow-up in a single center.
    Hu AB; Wu LW; Tai Q; Zhu XF; He XS
    J Dig Dis; 2013 Jan; 14(1):38-44. PubMed ID: 23134408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database.
    Kuo HT; Sampaio MS; Ye X; Reddy P; Martin P; Bunnapradist S
    Transplantation; 2010 May; 89(9):1134-40. PubMed ID: 20386364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection : an observational multicenter study.
    Saliba F; Lakehal M; Pageaux GP; Roche B; Vanlemmens C; Duvoux C; Dumortier J; Salamé E; Calmus Y; Maugendre D;
    Liver Transpl; 2007 Jan; 13(1):136-44. PubMed ID: 17192854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of donor and recipient SUMO4 rs237025 genetic variant with new-onset diabetes mellitus after liver transplantation in a Chinese population.
    Zhang T; Liu Y; Hu Y; Zhang X; Zhong L; Fan J; Peng Z
    Gene; 2017 Sep; 627():428-433. PubMed ID: 28689037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation.
    Guethoff S; Meiser BM; Groetzner J; Eifert S; Grinninger C; Ueberfuhr P; Reichart B; Hagl C; Kaczmarek I
    Transplantation; 2013 Feb; 95(4):629-34. PubMed ID: 23423270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between ADIPOQ gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation.
    Cen C; Fang HX; Yu SF; Liu JM; Liu YX; Zhou L; Yu J; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2017 Dec; 16(6):602-609. PubMed ID: 29291779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically Significant Drug Interaction Between Clotrimazole and Tacrolimus in Pancreas Transplant Recipients and Associated Risk of Allograft Rejection.
    Viesselmann CW; Descourouez JL; Jorgenson MR; Radke NA; Odorico JS
    Pharmacotherapy; 2016 Mar; 36(3):335-41. PubMed ID: 26877191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regression of new-onset diabetes mellitus after conversion from tacrolimus to cyclosporine in liver transplant patients: results of a pilot study.
    Lorho R; Hardwigsen J; Dumortier J; Pageaux GP; Durand F; Bizollon T; Blanc AS; Di Giambattista F; Duvoux C
    Clin Res Hepatol Gastroenterol; 2011 Jun; 35(6-7):482-8. PubMed ID: 21530445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab induction in non-hepatitis C positive liver transplant recipients.
    Levitsky J; Thudi K; Ison MG; Wang E; Abecassis M
    Liver Transpl; 2011 Jan; 17(1):32-7. PubMed ID: 21254342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New onset diabetes and impaired fasting glucose after liver transplant: risk analysis and the impact of tacrolimus dose.
    Lankarani KB; Eshraghian A; Nikeghbalian S; Janghorban P; Malek-Hosseini SA
    Exp Clin Transplant; 2014 Feb; 12(1):46-51. PubMed ID: 23902591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.